Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study

Brentuximab vedotin (BV) was initially approved in Japan for the treatment of relapsed/refractory (R/R) CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). As requested by the Japanese Ministry of Health, Labour and Welfare, we conducted a post-marketing surveill...

Descripción completa

Detalles Bibliográficos
Autores principales: Izutsu, Koji, Ogura, Michinori, Tobinai, Kensei, Hatake, Kiyohiko, Sakamoto, Shigeru, Nishimura, Masanori, Hoshino, Miyako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779085/
https://www.ncbi.nlm.nih.gov/pubmed/33392974
http://dx.doi.org/10.1007/s12185-020-03039-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779085/
https://www.ncbi.nlm.nih.gov/pubmed/33392974
http://dx.doi.org/10.1007/s12185-020-03039-w

Ejemplares similares